Innovating Works

BICO GROUP

Desconocido
iRETINA: Development of a multilayered and bioprinted iPSC-derived retinal model with use in preclinical and... BICO GROUP AB participó en un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Age-related macular degeneration (AMD) encompass the most prevalent cause of vision-loss in elderly people in developed countries. One of th...
2022-06-30 - 2026-02-28 | Financiado
OpenMIND: Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease BICO GROUP AB participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDEROPEN-01 A major challenge facing Europe is its ageing population and associated increase in diagnosed cases of neurodegenerative diseases (NDD). Par...
2022-06-30 - 2025-10-31 | Financiado
BioProS: Biointelligent Production Sensor to Measure Viral Activity BICO GROUP AB participó en un HORIZON EUROPE: HORIZON-CL4-2021-DIGITAL-EMERGING-01 We aim to transform virus biomanufacturing processes and enable new quality control strategies by a continuous, real-time capable biohybrid...
2022-06-23 - 2026-06-30 | Financiado
PRISM-LT: PRInted Symbiotic Materials as a dynamic platform for Living Tissues production BICO GROUP AB participó en un HORIZON EUROPE: HORIZON-EIC-2021-PATHFINDERCHALLENGES-01 The PRISM-LT aims at creating a flexible platform for next generation living tissue manufacturing based on Hybrid Living Materials. We pla...
2022-06-16 - 2027-10-31 | Financiado
LIFESAVER: Living Impact on Fetal Evolution Shelter Analyze Validate Empower Regulations BICO GROUP AB participó en un H2020: H2020-LC-GD-2020 In Europe about 75% of all neonatal deaths and 60% of all infant deaths occur in infants born preterm, and worldwide 450 neonatal deaths occ...
2021-09-28 - 2025-10-31 | Financiado
TRiAnkle: 3D BIOPRINTED PERSONALISED SCAFFOLDS FOR TISSUE REGENERATION OF ANKLE JOINT Tendinopathies and osteoarthritis (OA) are extremely common and these injuries associate with high health and socioeconomic costs, long-term...
2020-11-06 - 2025-06-30 | Financiado
REPAIR: RESTORING CARDIAC MECHANICAL FUNCTION BY POLYMERIC ARTIFICIAL MUSCULAR TISSUE BICO GROUP AB participó en un H2020: H2020-FETPROACT-2019-2020 Heart Failure (HF) and Atrial Fibrillation (AF) are both associated with impairment of cardiac mechanical function. To assist ventricular co...
2020-06-22 - 2025-05-31 | Financiado
GIOTTO: Active aGeIng and Osteoporosis The next challenge for smarT nanobiOmaterials and 3D technologies BICO GROUP AB participó en un H2020: H2020-NMBP-TR-IND-2018-2020 Osteoporosis is a systemic, degenerative disorder, predominantly affecting postmenopausal women (1 out of 3) but also men at an advanced age...
2018-12-12 - 2023-08-31 | Financiado
TUMOURPRINT: High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research BICO GROUP AB tramitó un H2020: H2020-EIC-SMEInst-2018-2020 CELLINK will develop and commercialise TumourPrint - a high throughput platform for bioprinting of live tumour models for pharmaceutical dru...
2018-10-29 - 2021-01-31 | Financiado
SilkFUSION: Genetically engineered human pluripotent stem cells functionalized silk fibroin platforms and bio i... BICO GROUP AB participó en un H2020: H2020-FETOPEN-2016-2017 "The demand for human platelets (plts) for medical research and clinical applications is massive. The primary goal of SilkFUSION is to engin...
2017-09-12 - 2022-10-31 | Financiado
CENSUS: Cell Based Models for Neurodegeneration Study and Use in Screening BICO GROUP AB participó en un H2020: H2020-FTIPilot-2016 1. Treatment of neurodegenerative disease is an unmet clinical challenge and patient care is a growing, unsustainable global healthcare burd...
2016-09-13 - 2019-09-30 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.